Nivolumab vs Opdivo Qvantig

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Nivolumab

Marketed by Bristol-Myers Squibb and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT01673867 · Phase 3 · completed

This was a large randomized trial comparing nivolumab with active treatment, but it was open-label rather than double-blinded. The prespecified primary endpoint, overall survival, favored nivolumab and was statistically significant; however, the lack of blinding limits the strength of the evidence.

Next expected readout: November 2026 · NCT02955290 (registry estimate)

Reported efficacy

Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68) (met)

Result source: NCT01673867

Opdivo Qvantig

Marketed by Bristol-Myers Squibb

Approved in Non-Small Cell Lung Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointNivolumabOpdivo Qvantig
PFS, median12.1 vs 8.1+4 vs placebon 275NCT03117049
22 other results
—Not reported
OS, median12.2 vs 9.4vs Docetaxeln 292NCT01673867
20 other results
—Not reported
ORR61.5% vs 50.5%+11 vs placebon 275NCT03117049
19 other results
  • 19.5% vs 12.8% n 292 · Phase 3 · secondary NCT01673867
  • 20% vs 8.8% n 135 · Phase 3 · secondary NCT01642004
  • 36.4% vs 29.7% n 396 · Phase 3 · secondary NCT02477826
  • 27.5% vs 29.7% n 396 · Phase 3 · secondary NCT02477826
  • 26.2% vs 29.7% n 187 · Phase 3 · secondary NCT02477826
  • 37.9% vs 29.7% n 177 · Phase 3 · secondary NCT02477826
  • 52.3% vs 29.7% n 377 · Phase 3 · secondary NCT02477826
  • 38.1% vs 29.7% n 126 · Phase 3 · secondary NCT02477826
  • 67.6% vs 64.5% n 287 · Phase 3 · secondary NCT04026412
  • 72.2% vs 64.5% n 320 · Phase 3 · secondary NCT04026412
  • 61.3% vs 57.9% n 287 · Phase 3 · secondary NCT04026412
  • 63.1% vs 57.9% n 320 · Phase 3 · secondary NCT04026412
  • 26.1% vs 33.5% n 211 · Phase 3 · secondary NCT02041533
  • 50.6% vs 43% wk 64 · n 158 · Phase 2 · primary NCT04623775
  • 14.5% 3 mg/kg · n 117 · Phase 2 · primary NCT01721759
  • 17.1% 480mg Q4W · n 129 · Phase 2 · secondary NCT03090737
  • 15.4% 3 mg/kg · n 117 · Phase 2 · secondary NCT01721759
  • 32.3% n 288 · Phase 2 · secondary NCT02659059
  • 47.2% n 36 · Phase 2 · secondary NCT02659059
—Not reported
Duration of response, median11 vs 7+4 vs placebon 275NCT03117049
12 other results
—Not reported

PFS, median

Nivolumab
12.1 vs 8.1+4 vs placebon 275NCT03117049
22 other results
Opdivo Qvantig
—Not reported

OS, median

Nivolumab
12.2 vs 9.4vs Docetaxeln 292NCT01673867
20 other results
Opdivo Qvantig
—Not reported

ORR

Nivolumab
61.5% vs 50.5%+11 vs placebon 275NCT03117049
19 other results
  • 19.5% vs 12.8% n 292 · Phase 3 · secondary NCT01673867
  • 20% vs 8.8% n 135 · Phase 3 · secondary NCT01642004
  • 36.4% vs 29.7% n 396 · Phase 3 · secondary NCT02477826
  • 27.5% vs 29.7% n 396 · Phase 3 · secondary NCT02477826
  • 26.2% vs 29.7% n 187 · Phase 3 · secondary NCT02477826
  • 37.9% vs 29.7% n 177 · Phase 3 · secondary NCT02477826
  • 52.3% vs 29.7% n 377 · Phase 3 · secondary NCT02477826
  • 38.1% vs 29.7% n 126 · Phase 3 · secondary NCT02477826
  • 67.6% vs 64.5% n 287 · Phase 3 · secondary NCT04026412
  • 72.2% vs 64.5% n 320 · Phase 3 · secondary NCT04026412
  • 61.3% vs 57.9% n 287 · Phase 3 · secondary NCT04026412
  • 63.1% vs 57.9% n 320 · Phase 3 · secondary NCT04026412
  • 26.1% vs 33.5% n 211 · Phase 3 · secondary NCT02041533
  • 50.6% vs 43% wk 64 · n 158 · Phase 2 · primary NCT04623775
  • 14.5% 3 mg/kg · n 117 · Phase 2 · primary NCT01721759
  • 17.1% 480mg Q4W · n 129 · Phase 2 · secondary NCT03090737
  • 15.4% 3 mg/kg · n 117 · Phase 2 · secondary NCT01721759
  • 32.3% n 288 · Phase 2 · secondary NCT02659059
  • 47.2% n 36 · Phase 2 · secondary NCT02659059
Opdivo Qvantig
—Not reported

Duration of response, median

Nivolumab
11 vs 7+4 vs placebon 275NCT03117049
12 other results
Opdivo Qvantig
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Opdivo Qvantig: no structured comparison results are available for Non-Small Cell Lung Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Nivolumab: 4 of 4 rows · Opdivo Qvantig: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricNivolumab
Dropout rate
—480 mga
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 43 more results
—3 mg/kg
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
1.7%Nivolumab
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—480 mg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—3 mg/kg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
3%Nivolumab
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
1.7%360 mg
NCT02998528 · Phase 3 · combination
0.9%3 mg/kg + 1 mg/kg
NCT02998528 · Phase 3 · combination
1.3%Part 1-Arm A: Nivolumab
NCT02477826 · Phase 3
1.3%Part 1-Arm B: Nivo + Ipi
NCT02477826 · Phase 3 · combination
1.1%Part 1-Arm D: Nivo + Ipi
NCT02477826 · Phase 3 · combination
2.8%Part 1-Arm G: Nivo + Chemo
NCT02477826 · Phase 3 · combination
0.5%Part 2 - Arm H: Nivolumab + Chemot
NCT02477826 · Phase 3 · combination
0%Part 3 -Arm J: Nivolumab + Ipilimu
NCT02477826 · Phase 3 · combination
66%
NCT03444766 · Phase 4 · registry result, not featured evidence
64.1%Arm A:Nivo + CCRT/Nivo + Ipi
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
56.9%Arm B: Nivo + CCRT/Nivo
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
73.1%
NCT03117049 · Phase 3 · registry result, not featured evidence
0.3%
NCT02613507 · Phase 3 · registry result, not featured evidence
2.1%Arm A: Nivolumab Plus Platinum-dou
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
2.7%Arm B: Nivolumab Plus Ipilimumab
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
1.5%
NCT02041533 · Phase 3 · registry result, not featured evidence
1.1%480 mg every 4 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
1.6%240 mg every 2 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
—Cohort A: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Cohort B: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
n/a: no completion milestoneNivolumab Monotherapy (Not Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Nivolumab Monotherapy (Pre-Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
88.2%HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
90.6%Non-HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
2.5%Part 1: Treatment A
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
0%Part 2: Treatment C
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
8.7%Arm A - Nivolumab
NCT03158129 · Phase 2 · registry result, not featured evidence
23.8%Arm B - Nivolumab + Ipilimumab
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
0%Arm C - Nivolumab + Chemotherapy
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
9.1%Arm D - Nivolumab + Ipilimumab + C
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
—Pixatimod (PG545) + Nivolumab + Cy
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
0%Pixatimod (PG545) + Nivolumab - Co
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
37.9%
NCT02350764 · Phase 2 · registry result, not featured evidence
—600 mg
NCT05005273 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone480mg Q4W
NCT03090737 · Phase 2 · registry result, not featured evidence
87.2%Nivolumab+Ipilimumab
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
88.9%Nivolumab+Ipilimumab+Chemotherapy
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone3 mg/kg
NCT01721759 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—480 mga
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 43 more results
—3 mg/kg
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
0.3%Nivolumab
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—480 mg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—3 mg/kg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
0.7%Nivolumab
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
0.6%360 mg
NCT02998528 · Phase 3 · combination
0%3 mg/kg + 1 mg/kg
NCT02998528 · Phase 3 · combination
0.3%Part 1-Arm A: Nivolumab
NCT02477826 · Phase 3
0%Part 1-Arm B: Nivo + Ipi
NCT02477826 · Phase 3 · combination
0.5%Part 1-Arm D: Nivo + Ipi
NCT02477826 · Phase 3 · combination
0%Part 1-Arm G: Nivo + Chemo
NCT02477826 · Phase 3 · combination
0.3%Part 2 - Arm H: Nivolumab + Chemot
NCT02477826 · Phase 3 · combination
0%Part 3 -Arm J: Nivolumab + Ipilimu
NCT02477826 · Phase 3 · combination
6%
NCT03444766 · Phase 4 · registry result, not featured evidence
—Arm A:Nivo + CCRT/Nivo + Ipi
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
—Arm B: Nivo + CCRT/Nivo
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
—
NCT03117049 · Phase 3 · registry result, not featured evidence
—
NCT02613507 · Phase 3 · registry result, not featured evidence
0.7%Arm A: Nivolumab Plus Platinum-dou
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
0%Arm B: Nivolumab Plus Ipilimumab
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
—
NCT02041533 · Phase 3 · registry result, not featured evidence
—480 mg every 4 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
—240 mg every 2 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
—Cohort A: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Cohort B: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
3.8%Nivolumab Monotherapy (Not Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Nivolumab Monotherapy (Pre-Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
11.8%HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
5%Non-HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
—Part 1: Treatment A
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
—Part 2: Treatment C
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
0%Arm A - Nivolumab
NCT03158129 · Phase 2 · registry result, not featured evidence
4.8%Arm B - Nivolumab + Ipilimumab
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
0%Arm C - Nivolumab + Chemotherapy
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
0%Arm D - Nivolumab + Ipilimumab + C
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
—Pixatimod (PG545) + Nivolumab + Cy
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
—Pixatimod (PG545) + Nivolumab - Co
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
13.8%
NCT02350764 · Phase 2 · registry result, not featured evidence
—600 mg
NCT05005273 · Phase 2 · registry result, not featured evidence · combination
5.4%480mg Q4W
NCT03090737 · Phase 2 · registry result, not featured evidence
11.1%Nivolumab+Ipilimumab
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
11.1%Nivolumab+Ipilimumab+Chemotherapy
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
9.4%3 mg/kg
NCT01721759 · Phase 2 · registry result, not featured evidence
Serious AEs
33.3%480 mga
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 43 more results
59.9%3 mg/kg
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—Nivolumab
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
16.7%480 mg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
64.9%3 mg/kg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—Nivolumab
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
30.1%360 mg
NCT02998528 · Phase 3 · combination
27%3 mg/kg + 1 mg/kg
NCT02998528 · Phase 3 · combination
61.1%Part 1-Arm A: Nivolumab
NCT02477826 · Phase 3
70.3%Part 1-Arm B: Nivo + Ipi
NCT02477826 · Phase 3 · combination
69.2%Part 1-Arm D: Nivo + Ipi
NCT02477826 · Phase 3 · combination
65.1%Part 1-Arm G: Nivo + Chemo
NCT02477826 · Phase 3 · combination
64%Part 2 - Arm H: Nivolumab + Chemot
NCT02477826 · Phase 3 · combination
61.9%Part 3 -Arm J: Nivolumab + Ipilimu
NCT02477826 · Phase 3 · combination
30%
NCT03444766 · Phase 4 · registry result, not featured evidence
63.8%Arm A:Nivo + CCRT/Nivo + Ipi
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
56.9%Arm B: Nivo + CCRT/Nivo
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
56.4%
NCT03117049 · Phase 3 · registry result, not featured evidence
54.3%
NCT02613507 · Phase 3 · registry result, not featured evidence
54.6%Arm A: Nivolumab Plus Platinum-dou
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
64.8%Arm B: Nivolumab Plus Ipilimumab
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
73%
NCT02041533 · Phase 3 · registry result, not featured evidence
34.8%480 mg every 4 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
39.4%240 mg every 2 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
44.9%Cohort A: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
41.6%Cohort B: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Nivolumab Monotherapy (Not Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
60.9%Nivolumab Monotherapy (Pre-Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
70.6%HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
41%Non-HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
59.7%Part 1: Treatment A
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
65.2%Part 2: Treatment C
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
17.4%Arm A - Nivolumab
NCT03158129 · Phase 2 · registry result, not featured evidence
14.3%Arm B - Nivolumab + Ipilimumab
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
31.8%Arm C - Nivolumab + Chemotherapy
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
13.6%Arm D - Nivolumab + Ipilimumab + C
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
37.5%Pixatimod (PG545) + Nivolumab + Cy
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
20%Pixatimod (PG545) + Nivolumab - Co
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
75.9%
NCT02350764 · Phase 2 · registry result, not featured evidence
100%600 mg
NCT05005273 · Phase 2 · registry result, not featured evidence · combination
43.4%480mg Q4W
NCT03090737 · Phase 2 · registry result, not featured evidence
59.4%Nivolumab+Ipilimumab
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
72.2%Nivolumab+Ipilimumab+Chemotherapy
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
75.2%3 mg/kg
NCT01721759 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
480 mga
cough 33.3%
arthralgia 20%
rash 20%
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 40 more results
3 mg/kg
fatigue 33.4%
decreased appetite 31.7%
cough 28.9%
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
480 mg
nausea 33.3%
vomiting 33.3%
abdominal pain 16.7%
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
3 mg/kg
dyspnoea 35.9%
cough 34.4%
fatigue 32.1%
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
360 mg
nausea 41.5%
constipation 35.8%
anaemia 35.2%
NCT02998528 · Phase 3 · combination
3 mg/kg + 1 mg/kg
constipation 21.6%
fatigue 21.6%
nausea 21.6%
NCT02998528 · Phase 3 · combination
decreased appetite 24.8%
dyspnoea 23.8%
diarrhoea 22.5%
NCT02477826 · Phase 3
decreased appetite 33.2%
fatigue 27.4%
diarrhoea 26.1%
NCT02477826 · Phase 3 · combination
decreased appetite 33%
dyspnoea 25.4%
diarrhoea 23.8%
NCT02477826 · Phase 3 · combination
anaemia 46.5%
nausea 45.9%
constipation 36.6%
NCT02477826 · Phase 3 · combination
anaemia 46.4%
nausea 33.6%
decreased appetite 28%
NCT02477826 · Phase 3 · combination
anaemia 50%
hyponatraemia 37.3%
aspartate aminotransferase increased 36.5%
NCT02477826 · Phase 3 · combination
cough 24%
pyrexia 21%
vomiting 17%
NCT03444766 · Phase 4 · registry result, not featured evidence
anaemia 44%
nausea 34.8%
constipation 29.1%
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
anaemia 41.5%
nausea 32.7%
cough 26.1%
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
constipation 54.9% (placebo 48.7%)
alopecia 52.4% (placebo 54.5%)
peripheral sensory neuropathy 44.3% (placebo 42.2%)
NCT03117049 · Phase 3 · registry result, not featured evidence
anaemia 34.7%
decreased appetite 31.5%
fatigue 31.2%
NCT02613507 · Phase 3 · registry result, not featured evidence
anaemia 46.8%
nausea 44.7%
constipation 36.9%
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
constipation 29.6%
pruritus 25.4%
diarrhoea 23.9%
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
fatigue 40.4%
decreased appetite 34.1%
nausea 32.2%
NCT02041533 · Phase 3 · registry result, not featured evidence
480 mg every 4 weeks
diarrhoea 16.9%
pruritus 16.9%
fatigue 15.7%
NCT02713867 · Phase 3 · registry result, not featured evidence
240 mg every 2 weeks
pruritus 23.3%
diarrhoea 22.8%
fatigue 22.2%
NCT02713867 · Phase 3 · registry result, not featured evidence
diarrhoea 28.3%
arthralgia 23.6%
upper respiratory tract infection 22%
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
cough 17.6%
weight decreased 16%
arthralgia 14.4%
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
fatigue 36.1%
dyspnoea 23.7%
nausea 23.2%
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
anaemia 41.2%
cough 41.2%
hyponatraemia 35.3%
NCT03195491 · Phase 3 · registry result, not featured evidence
anaemia 40.5%
decreased appetite 24.5%
cough 22.2%
NCT03195491 · Phase 3 · registry result, not featured evidence
anaemia 66.2%
fatigue 42.9%
nausea 42.9%
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
anaemia 69%
nausea 34.8%
thrombocytopenia 29.7%
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
fatigue 34.8%
anemia 30.4%
rash acneiform 26.1%
NCT03158129 · Phase 2 · registry result, not featured evidence
rash acneiform 61.9%
cough 38.1%
fatigue 38.1%
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
nausea 81.8%
fatigue 72.7%
anemia 54.5%
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
anemia 50%
diarrhea 40.9%
nausea 40.9%
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
anemia 62.5%
fatigue 50%
hyponatremia 50%
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
activated partial thromboplastin time prolonged 80%
hypertriglyceridemia 60%
hyponatremia 60%
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
hyperglycemia 100%
hypoalbuminemia 93.1%
anemia 75.9%
NCT02350764 · Phase 2 · registry result, not featured evidence
600 mg
blood alkaline phosphatase increased 100%
blood lactate dehydrogenase increased 100%
bronchitis 100%
NCT05005273 · Phase 2 · registry result, not featured evidence · combination
480mg Q4W
anaemia 28.7%
blood alkaline phosphatase increased 24.8%
rash 20.2%
NCT03090737 · Phase 2 · registry result, not featured evidence
fatigue 55.2%
diarrhoea 38.5%
nausea 38.2%
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
fatigue 55.6%
pruritus 47.2%
nausea 44.4%
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
3 mg/kg
fatigue 53%
decreased appetite 39.3%
dyspnoea 38.5%
NCT01721759 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 38 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Nivolumab

Overall Survival NA vs 73.72 Platinum Doublet Chemo months360 mg
time to event · months
NCT02998528 · Phase 3 · combination
show 18 more results
12.19 vs 9.36 Docetaxel months
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
12.21 vs 9.49 Docetaxel months
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
9.23 vs 6.01 Docetaxel months
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
9.23 vs 6.01 Docetaxel months
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
17.12 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3 · combination
15.7 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3
17.45 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3 · combination
15.21 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3 · combination
18.27 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3 · combination
20.99 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3 · combination
34.6 vs 39.79 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
39.49 vs 39.79 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
25.4 vs 24.7 placebo months
NCT03117049 · Phase 3 · registry result, not featured evidence
11.99 vs 9.63 Docetaxel months
NCT02613507 · Phase 3 · registry result, not featured evidence
19.35 vs 15.9 Platinum Doublet Chemotherapy months
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
17.12 vs 15.9 Platinum Doublet Chemotherapy months
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
14.36 vs 13.21 Investigator Choice of Chemotherapy months
NCT02041533 · Phase 3 · registry result, not featured evidence
13.73 vs 13.8 Investigator Choice of Chemotherapy months
NCT02041533 · Phase 3 · registry result, not featured evidence
ORR 19.5% (n=292) vs 12.8% (n=290) Docetaxel
responder rate · % of participants
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 14 more results
20% (n=135) vs 8.8% (n=137) Docetaxel
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
36.4% (n=396) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3 · combination
27.5% (n=396) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3
26.2% (n=187) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3 · combination
37.9% (n=177) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3 · combination
52.3% (n=377) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3 · combination
38.1% (n=126) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3 · combination
67.6% (n=287) vs 64.5% (n=318) Durva
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
72.2% (n=320) vs 64.5% (n=318) Durva
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
61.3% (n=287) vs 57.9% (n=318) Durva
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
63.1% (n=320) vs 57.9% (n=318) Durva
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
61.5% (n=275) vs 50.5% (n=275) placebo
NCT03117049 · Phase 3 · registry result, not featured evidence
26.1% (n=211) vs 33.5% (n=212) Investigator Choice of Chemotherapy
NCT02041533 · Phase 3 · registry result, not featured evidence
50.6% (n=158) vs 43% (n=151) Nivolumab + Chemotherapy @ 64wk
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
Time to Response 2.1 vs 2.73 Docetaxel months
time to event · months
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 5 more results
2.23 vs 2.09 Docetaxel months
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
2.92 vs 2.92 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
2.96 vs 2.92 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
2.96 vs 2.89 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
2.92 vs 2.89 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
Duration of Response 17.15 vs 5.55 Docetaxel months
time to event · months
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 9 more results
24.51 vs 8.41 Docetaxel months
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
25.76 vs 25.17 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
31.84 vs 25.17 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
22.83 vs 27.93 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
33.18 vs 27.93 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
11 vs 7 placebo months
NCT03117049 · Phase 3 · registry result, not featured evidence
6.67 vs 5.55 Platinum Doublet Chemotherapy months
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
50.04 vs 5.55 Platinum Doublet Chemotherapy months
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
8.41 vs 7.1 Nivolumab + Chemotherapy months
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
PFS 2.33 vs 4.44 Docetaxel months
time to event · months
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 17 more results
3.48 vs 2.83 Docetaxel months
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
5.06 vs 5.55 Chemotherapy months
NCT02477826 · Phase 3 · combination
4.17 vs 5.55 Chemotherapy months
NCT02477826 · Phase 3
4.9 vs 5.55 Chemotherapy months
NCT02477826 · Phase 3 · combination
5.55 vs 5.55 Chemotherapy months
NCT02477826 · Phase 3 · combination
8.34 vs 5.55 Chemotherapy months
NCT02477826 · Phase 3 · combination
5.78 vs 5.55 Chemotherapy months
NCT02477826 · Phase 3 · combination
16.69 vs 15.64 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
16.82 vs 15.67 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
17.38 vs 15.67 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
16.82 vs 16.53 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
17.71 vs 16.53 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
12.1 vs 8.1 placebo months
NCT03117049 · Phase 3 · registry result, not featured evidence
5.59 vs 5.45 Platinum Doublet Chemotherapy months
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
1.54 vs 5.45 Platinum Doublet Chemotherapy months
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
4.21 vs 5.88 Investigator Choice of Chemotherapy months
NCT02041533 · Phase 3 · registry result, not featured evidence
4.21 vs 5.82 Investigator Choice of Chemotherapy months
NCT02041533 · Phase 3 · registry result, not featured evidence
Disease-related Symptom Improvement 17.8% (n=292) vs 19.7% (n=290) Docetaxel @ 12wk
responder rate · % of participants
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 2 more results
18.5% (n=135) vs 21.2% (n=137) Docetaxel @ 12wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
35.4% (n=271) vs 33.7% (n=270) Investigator Choice of Chemotherapy @ 12wk
NCT02041533 · Phase 3 · registry result, not featured evidence
Overall Survival 63.7% (n=135) vs 50.7% (n=137) Docetaxel @ 26wk
absolute value · percentage points
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 11 more results
42.2% (n=135) vs 24.3% (n=137) Docetaxel @ 52wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
28.1% (n=135) vs 12.5% (n=137) Docetaxel @ 78wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
63.7% (n=135) vs 50.4% (n=137) Docetaxel @ 26wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
42.2% (n=135) vs 24.1% (n=137) Docetaxel @ 52wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
28.1% (n=135) vs 12.4% (n=137) Docetaxel @ 78wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
23% (n=135) vs 8% (n=137) Docetaxel @ 104wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
15.6% (n=135) vs 5.8% (n=137) Docetaxel @ 156wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
13.1% (n=135) vs 4.4% (n=137) Docetaxel @ 208wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
12.3% (n=135) vs 3.6% (n=137) Docetaxel @ 260wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
11.4% (n=135) vs 2.7% (n=137) Docetaxel @ 312wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
9.6% (n=135) vs 0% (n=137) Docetaxel @ 364wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
PFS 38.4% (n=135) vs 22.6% (n=137) Docetaxel @ 26wk
responder rate · % of participants
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 8 more results
21% (n=135) vs 7.2% (n=137) Docetaxel @ 52wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
15.87% (n=135) vs 1.8% (n=137) Docetaxel @ 78wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
14.8% (n=135) vs NA Docetaxel @ 104wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
11% (n=135) vs NA Docetaxel @ 156wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
8.9% (n=135) vs NA Docetaxel @ 208wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
8.9% (n=135) vs NA Docetaxel @ 260wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
7.6% (n=135) vs NA Docetaxel @ 312wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
6.1% (n=135) vs NA Docetaxel @ 364wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Event-Free Survival 31.57 vs 20.8 Platinum Doublet Chemo months360 mg
time to event · months
NCT02998528 · Phase 3 · combination
show 1 more result
59.6 vs 21.06 Platinum Doublet Chemo months360 mg
NCT02998528 · Phase 3 · combination
Pathologic Complete 24% (n=179) vs 2.2% (n=179) Platinum Doublet Chemo360 mg
responder rate · % of participants
NCT02998528 · Phase 3 · combination · converted to % from 43 Participants as posted
Major Pathologic 36.9% (n=179) vs 8.9% (n=179) Platinum Doublet Chemo360 mg
responder rate · % of participants
NCT02998528 · Phase 3 · combination · converted to % from 66 Participants as posted
Time to Death or Distant Metastasis 64.66 vs 36.76 Platinum Doublet Chemo months360 mg
time to event · months
NCT02998528 · Phase 3 · combination
show 2 more results
30.65 vs 30.36 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
36.14 vs 30.36 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination

+ 41 further endpoints in the CSV export.

Urothelial Carcinoma

Shared mechanism: PD-1 · full Urothelial Carcinoma pipeline

Nivolumab

Marketed by Bristol-Myers Squibb and partners

Approved in Urothelial Carcinomamonoclonal antibody
Partial signal

NCT03036098 · Phase 3 · completed

This was a large randomized trial against standard chemotherapy, but it was open-label. Three of the four primary comparisons were statistically significant, while overall survival in PD-L1 positive patients given nivolumab plus ipilimumab has no posted significance test, so the overall result is mixed.

Next expected readout: December 2026 · NCT06682728 (registry estimate)

Reported efficacy

Overall Survival (OS) in Cisplatin-ineligible Randomized Participants for Primary Study (From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)); Overall Survival (OS) in Programmed Death-Ligand 1 (PD-L1) Positive (≥ 1%) Randomized Participants by Immunohistochemistry (IHC) for Primary Study (From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)); Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) [Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1] in Cisplatin-eligible Participants for Sub-study (From the date of randomization to the date of first documented disease progression or death due to any cause, whichever occurs first (up to approximately 89 months)); Overall Survival (OS) in Cisplatin-eligible Participants for Sub-study (From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)): Sub-study (cisplatin-eligible), nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin: PFS HR 0.72 (95% CI 0.59 to 0.88), p=0.0018; OS median 21.7 vs 18.9 months, HR 0.78 (95% CI 0.63 to 0.96), p=0.0171. Primary study, nivolumab + ipilimumab vs chemotherapy: OS in PD-L1 >=1% 16.3 vs 14.4 months, primary not met per BMS; OS in cisplatin-ineligible 19.1 vs 13.2 months, HR 0.79 (95% CI 0.64 to 0.97), posted p=0.0032 (CT.gov posted results). (mixed)

Result source: NCT03036098

Opdivo Qvantig

Marketed by Bristol-Myers Squibb

Approved in Urothelial Carcinomamonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Urothelial Carcinoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Opdivo Qvantig: no structured comparison results are available for Urothelial Carcinoma.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Nivolumab

ORR 14.9% (n=429)0.006 mg/kg q3w + 360 mg q3w
event count · % of participants
No placebo or comparator arm
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 64 Participants as posted
show 1 more result
17.6% (n=17)*
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
Available safety results

Nivolumab

Dropout rate
0%0.009 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
show 9 more results
0%0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
20%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
17.2%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
10.5%Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
Discontinued due to AEs
—0.009 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
show 9 more results
—0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
Serious AEs
66.7%0.009 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
show 9 more results
50%0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
36%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
44.7%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
60%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
62.5%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
42.1%Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
Most frequent reported AEs
0.009 mg/kg q3w + 360 mg q3w
pyrexia 100%
rash 100%
chills 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
show 9 more results
0.006 mg/kg q3w + 240 mg q2w
arthralgia 100%
fatigue 100%
headache 100%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q2w + 240 mg q2w
chills 100%
pyrexia 100%
back pain 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q3w + 360 mg q3w
fatigue 76%
chills 64%
cough 60%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q3w + 360 mg q3w
fatigue 50.6%
pyrexia 47.9%
nausea 40.1%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.003 mg/kg q2w + 240 mg q2w
chills 100%
nasal congestion 100%
arthralgia 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 90%
diarrhoea 80%
nausea 80%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
diarrhoea 75%
influenza like illness 75%
pruritus 75%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
decreased appetite 100%
fatigue 100%
influenza like illness 100%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 78.9%
influenza like illness 68.4%
nausea 57.9%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination

Hepatocellular Carcinoma

Shared mechanism: PD-1 · full Hepatocellular Carcinoma pipeline

Nivolumab

Marketed by Bristol-Myers Squibb and partners

Approved in Hepatocellular Carcinomamonoclonal antibody
Partial signal

NCT04039607 · Phase 3 · completed

This was a large randomized phase 3 trial against an active comparator, and its primary endpoint, overall survival, was met with statistical significance. Patients and doctors knew which treatment was given, but survival is an objective outcome that this knowledge cannot change; an open-label design still keeps the evidence below the top level.

Next expected readout: December 2026 · NCT07176650 (registry estimate)

No aligned efficacy figure on record for this race.

Opdivo Qvantig

Marketed by Bristol-Myers Squibb

Approved in Hepatocellular Carcinomamonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Hepatocellular Carcinoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Opdivo Qvantig: no structured comparison results are available for Hepatocellular Carcinoma.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Nivolumab

PFS 5.26 months
time to event · months
No placebo or comparator arm
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
show 1 more result
5.39 months
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
ORR 24% (n=25)
responder rate · % of participants
No placebo or comparator arm
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
show 1 more result
0% (n=1)
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
Duration of Response 9.03 months
time to event · months
No placebo or comparator arm
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
Time to Response 4.2 months
time to event · months
No placebo or comparator arm
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
Overall Survival 11.99 months
time to event · months
No placebo or comparator arm
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
show 1 more result
14.52 months
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
Available safety results

Nivolumab

Dropout rate
0%Galunisertib + Nivolumab (Cohort 1
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
show 5 more results
20%Galunisertib + Nivolumab (Cohort 2
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
0%Galunisertib + Nivolumab (Cohort 3
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
0%Galunisertib + Nivolumab (Cohort 4
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
—Galunisertib + Nivolumab (HCC) Pha
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
—Galunisertib + Nivolumab (NSCLC) P
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
Discontinued due to AEs
0%Galunisertib + Nivolumab (Cohort 1
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
show 5 more results
0%Galunisertib + Nivolumab (Cohort 2
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
0%Galunisertib + Nivolumab (Cohort 3
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
0%Galunisertib + Nivolumab (Cohort 4
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
—Galunisertib + Nivolumab (HCC) Pha
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
—Galunisertib + Nivolumab (NSCLC) P
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
Serious AEs
33.3%Galunisertib + Nivolumab (Cohort 1
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
show 5 more results
40%Galunisertib + Nivolumab (Cohort 2
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Galunisertib + Nivolumab (Cohort 3
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
50%Galunisertib + Nivolumab (Cohort 4
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
0%Galunisertib + Nivolumab (HCC) Pha
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
52%Galunisertib + Nivolumab (NSCLC) P
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
Most frequent reported AEs
vomiting 66.7%
dehydration 33.3%
depression 33.3%
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
show 5 more results
diarrhoea 40%
pulmonary embolism 40%
abdominal pain 20%
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
dyspnoea 33.3%
headache 33.3%
hyperglycaemia 33.3%
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
amylase increased 75%
aspartate aminotransferase increased 50%
blood alkaline phosphatase increased 50%
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
gingivitis 100%
rhinorrhoea 100%
abdominal distension 0%
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
pruritus 36%
decreased appetite 28%
diarrhoea 28%
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination

Gastric Cancer

Shared mechanism: PD-1 · full Gastric Cancer pipeline

Nivolumab

Marketed by Bristol-Myers Squibb and partners

Approved in Gastric Cancermonoclonal antibody
Partial signal

NCT02872116 · Phase 3 · completed

The trial randomized 2,031 participants to nivolumab plus chemotherapy or active chemotherapy control, but treatment assignment was open-label rather than double-blinded. Its clinical primary endpoints were met, with statistically significant improvements in both overall survival and progression-free survival; however, the available record does not report a power calculation, so the evidence is graded moderate.

Next expected readout: December 2026 · NCT04900818 (registry estimate)

No aligned efficacy figure on record for this race.

Opdivo Qvantig

Marketed by Bristol-Myers Squibb

Approved in Gastric Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Gastric Cancer

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Opdivo Qvantig: no structured comparison results are available for Gastric Cancer.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Nivolumab

ORR 14.9% (n=429)0.006 mg/kg q3w + 360 mg q3w
event count · % of participants
No placebo or comparator arm
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 64 Participants as posted
show 1 more result
17.6% (n=17)*
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
Available safety results

Nivolumab

Dropout rate
0%0.009 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
show 9 more results
0%0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
20%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
17.2%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
10.5%Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
Discontinued due to AEs
—0.009 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
show 9 more results
—0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
Serious AEs
66.7%0.009 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
show 9 more results
50%0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
36%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
44.7%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
60%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
62.5%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
42.1%Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
Most frequent reported AEs
0.009 mg/kg q3w + 360 mg q3w
pyrexia 100%
rash 100%
chills 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
show 9 more results
0.006 mg/kg q3w + 240 mg q2w
arthralgia 100%
fatigue 100%
headache 100%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q2w + 240 mg q2w
chills 100%
pyrexia 100%
back pain 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q3w + 360 mg q3w
fatigue 76%
chills 64%
cough 60%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q3w + 360 mg q3w
fatigue 50.6%
pyrexia 47.9%
nausea 40.1%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.003 mg/kg q2w + 240 mg q2w
chills 100%
nasal congestion 100%
arthralgia 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 90%
diarrhoea 80%
nausea 80%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
diarrhoea 75%
influenza like illness 75%
pruritus 75%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
decreased appetite 100%
fatigue 100%
influenza like illness 100%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 78.9%
influenza like illness 68.4%
nausea 57.9%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination

Melanoma

Shared mechanism: PD-1 · full Melanoma pipeline

Nivolumab

Marketed by Bristol-Myers Squibb and partners

Approved in Melanomamonoclonal antibody
Partial signal

NCT01721746 · Phase 3 · completed

This was a large randomized trial against chemotherapy, but it was open-label. Overall survival, an objective outcome, was not significantly better with nivolumab, although more patients had a tumour response.

Next expected readout: November 2026 · NCT06712927 (registry estimate)

Reported efficacy

Recurrence-free Survival (RFS) (up to 36 months): Recurrence-free Survival (RFS) (up to 36 months): Nivolumab 3 mg/kg 52.37 Months | Ipilimumab 10 mg/kg 24.08 Months (95% CI 16.56 to 35.09) (met)

Result source: NCT02388906

Opdivo Qvantig

Marketed by Bristol-Myers Squibb

Approved in Melanomamonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Melanoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Opdivo Qvantig: no structured comparison results are available for Melanoma.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Nivolumab

Stable Disease 40% (n=5)
absolute value · percentage points
No placebo or comparator arm
Stable Disease (SD)
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
37.5% (n=8)
Stable Disease (SD)
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
Progressive Disease 60% (n=5)
absolute value · percentage points
No placebo or comparator arm
Progressive Disease (PD)
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
62.5% (n=8)
Progressive Disease (PD)
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
PFS 6mo 20% (n=5) @ 24wk
absolute value · percentage points
No placebo or comparator arm
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
13% (n=8) @ 24wk
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
PFS 12mo 0% (n=5) @ 52wk
absolute value · percentage points
No placebo or comparator arm
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
13% (n=8) @ 52wk
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
PFS 24 0% (n=5) @ 104wk
absolute value · percentage points
No placebo or comparator arm
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0% (n=8) @ 104wk
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
PFS 18.37 months30 mg
time to event · months
No placebo or comparator arm
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 79.6 weeks as posted
show 8 more results
2.33 months*30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 10.1 weeks as posted
3.37 months*30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 14.6 weeks as posted
2 months
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
2 months
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
4.11 months
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
1.97 months
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
3.43 months
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
3.65 months
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
OS 6mo 75% (n=5) @ 24wk
absolute value · percentage points
No placebo or comparator arm
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
50% (n=8) @ 24wk
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
OS Rate at 12 0% (n=5) @ 52wk
absolute value · percentage points
No placebo or comparator arm
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
19% (n=8) @ 52wk
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
OS24 0% (n=5) @ 104wk
absolute value · percentage points
No placebo or comparator arm
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0% (n=8) @ 104wk
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
ORR 56.6% (n=53)30 mg
absolute value · percentage points
No placebo or comparator arm
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
22.7% (n=22)30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
16.7% (n=6)30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
Disease Control 84.9% (n=53)30 mg
absolute value · percentage points
No placebo or comparator arm
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
68.2% (n=22)30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
66.7% (n=6)30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
Duration of Response 30.96 monthsBMS-986205 200 mg
time to event · months
No placebo or comparator arm
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 134.14 weeks as posted
show 14 more results
17.57 months*BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 76.14 weeks as posted
NA monthsBMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
NA monthsBMS-986205 200 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
NA monthsBMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
NA monthsBMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
12.03 months*BMS-986205 50 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 52.14 weeks as posted
NA months30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
7.38 months*30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 32 weeks as posted
20.63 months*30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 89.4 weeks as posted
NA months
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
12.72 months*
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 55.14 weeks as posted
NA months
NCT02658890 · Phase 1/2 · registry result, not featured evidence
NA months
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
NA months
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination

+ 7 further endpoints in the CSV export.

Available safety results

Nivolumab

Dropout rate
—Pixatimod (PG545) + Nivolumab + Cy
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 66 more results
0%Pixatimod (PG545) + Nivolumab - Co
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
100%40 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
100%30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
97.5%30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
100%20 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
0%0.009 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
20%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
17.2%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
10.5%Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—400 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
—BMS-986205 400 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%BMS-986205 400 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%BMS-986205 200 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%BMS-986205 100 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
0%BMS-986205 50 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%50 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
0%BMS-986205 25 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%Food Effect/ Relative BA (FE BA) S
NCT02658890 · Phase 1/2 · registry result, not featured evidence
0%Part 2: Exp ML Anti-PDL1+CTLA4
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 2: Exp ML BRAF-MT- NIVO
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—0.3 mg/kg + Nivolumab
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—0.1 mg/kg + Nivolumab
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—0.03 mg/kg + Nivolumab
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort 1(Arm)/ inNSCLC (Phase 2) -
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort 2(Arm)/ PD1-MM (Phase 2) -
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort 3A(Arm)/ PD1-NSCLC (Phase 2
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort 3B(Arm)/ PD1-NSCLC (Phase 2
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
100%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
99.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
96.5%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
85.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
0%280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
—Pixatimod (PG545) + Nivolumab + Cy
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 66 more results
—Pixatimod (PG545) + Nivolumab - Co
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
—40 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
—30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
—30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
—20 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
—0.009 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—400 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
—BMS-986205 400 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 400 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 200 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 100 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
—BMS-986205 50 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
—BMS-986205 25 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—Food Effect/ Relative BA (FE BA) S
NCT02658890 · Phase 1/2 · registry result, not featured evidence
—Part 2: Exp ML Anti-PDL1+CTLA4
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—Part 2: Exp ML BRAF-MT- NIVO
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—0.3 mg/kg + Nivolumab
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—0.1 mg/kg + Nivolumab
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—0.03 mg/kg + Nivolumab
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort 1(Arm)/ inNSCLC (Phase 2) -
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort 2(Arm)/ PD1-MM (Phase 2) -
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort 3A(Arm)/ PD1-NSCLC (Phase 2
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort 3B(Arm)/ PD1-NSCLC (Phase 2
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
37.5%Pixatimod (PG545) + Nivolumab + Cy
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 66 more results
20%Pixatimod (PG545) + Nivolumab - Co
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
57.1%40 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
85.7%30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
49.4%30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
33.3%20 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
66.7%0.009 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
50%0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
36%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
44.7%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
60%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
62.5%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
42.1%Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
100%400 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
83.3%BMS-986205 400 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 400 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
66.7%BMS-986205 200 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
68.8%BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
82.4%BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
64.3%BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
66.7%BMS-986205 100 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
85.7%BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
83.3%BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
80%BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
100%50 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
60%BMS-986205 50 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%50 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
71.4%BMS-986205 25 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
50%Food Effect/ Relative BA (FE BA) S
NCT02658890 · Phase 1/2 · registry result, not featured evidence
58.8%Part 2: Exp ML Anti-PDL1+CTLA4
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
16.7%Part 2: Exp ML BRAF-MT- NIVO
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%0.3 mg/kg + Nivolumab
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
33.3%0.1 mg/kg + Nivolumab
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
33.3%0.03 mg/kg + Nivolumab
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
47.2%Cohort 1(Arm)/ inNSCLC (Phase 2) -
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
15.8%Cohort 2(Arm)/ PD1-MM (Phase 2) -
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
42.9%Cohort 3A(Arm)/ PD1-NSCLC (Phase 2
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
46.4%Cohort 3B(Arm)/ PD1-NSCLC (Phase 2
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
40%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
60%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
51.3%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
47.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
56.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
55.6%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
66.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
66.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
16.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
57.1%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
20%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
40%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
0%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
75%0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
14.3%280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
66.7%140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
100%140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
anemia 62.5%
fatigue 50%
hyponatremia 50%
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 63 more results
activated partial thromboplastin time prolonged 80%
hypertriglyceridemia 60%
hyponatremia 60%
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
40 mg
anaemia 57.1%
decreased appetite 57.1%
contusion 42.9%
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
30 mg
fatigue 71.4%
weight decreased 71.4%
anaemia 57.1%
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
30 mg
fatigue 65.8%
nausea 55.7%
diarrhoea 53.2%
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
20 mg
diarrhoea 66.7%
dyspnoea 66.7%
fatigue 66.7%
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
0.009 mg/kg q3w + 360 mg q3w
pyrexia 100%
rash 100%
chills 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q3w + 240 mg q2w
arthralgia 100%
fatigue 100%
headache 100%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q2w + 240 mg q2w
chills 100%
pyrexia 100%
back pain 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q3w + 360 mg q3w
fatigue 76%
chills 64%
cough 60%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q3w + 360 mg q3w
fatigue 50.6%
pyrexia 47.9%
nausea 40.1%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.003 mg/kg q2w + 240 mg q2w
chills 100%
nasal congestion 100%
arthralgia 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 90%
diarrhoea 80%
nausea 80%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
diarrhoea 75%
influenza like illness 75%
pruritus 75%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
decreased appetite 100%
fatigue 100%
influenza like illness 100%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 78.9%
influenza like illness 68.4%
nausea 57.9%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
400 mg
abdominal discomfort 0%
abdominal distension 0%
abdominal hernia 0%
NCT02658890 · Phase 1/2 · registry result, not featured evidence
BMS-986205 400 mg + nivolumab 240 mg
constipation 66.7%
fatigue 66.7%
vomiting 66.7%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
BMS-986205 200 mg + nivolumab 240 mg
fatigue 66.7%
nausea 44.4%
vomiting 44.4%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
BMS-986205 200 mg
decreased appetite 43.8%
fatigue 43.8%
nausea 43.8%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
BMS-986205 200 mg
fatigue 52.9%
alanine aminotransferase increased 35.3%
urinary tract infection 35.3%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
BMS-986205 200 mg
fatigue 42.9%
constipation 28.6%
nausea 28.6%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
BMS-986205 100 mg + nivolumab 240 mg
fatigue 58.3%
anaemia 50%
decreased appetite 50%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
BMS-986205 100 mg
asthenia 28.6%
decreased appetite 28.6%
nausea 28.6%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
BMS-986205 100 mg
decreased appetite 55.6%
nausea 50%
vomiting 38.9%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
BMS-986205 100 mg
decreased appetite 33.3%
asthenia 26.7%
constipation 26.7%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
50 mg
headache 100%
oedema peripheral 100%
vomiting 100%
NCT02658890 · Phase 1/2 · registry result, not featured evidence
BMS-986205 50 mg + nivolumab 240 mg
fatigue 70%
vomiting 60%
decreased appetite 50%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
50 mg
abdominal discomfort 0%
abdominal distension 0%
abdominal hernia 0%
NCT02658890 · Phase 1/2 · registry result, not featured evidence
BMS-986205 25 mg + nivolumab 240 mg
fatigue 57.1%
nausea 57.1%
vomiting 57.1%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 64.3%
nausea 42.9%
diarrhoea 35.7%
NCT02658890 · Phase 1/2 · registry result, not featured evidence
constipation 29.4%
fatigue 29.4%
nausea 29.4%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
diarrhoea 50%
fatigue 50%
headache 50%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0.3 mg/kg + Nivolumab
chills 100%
nausea 100%
pruritus 100%
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
0.1 mg/kg + Nivolumab
anaemia 66.7%
chills 66.7%
decreased appetite 66.7%
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
0.03 mg/kg + Nivolumab
fatigue 100%
anxiety 33.3%
arthralgia 33.3%
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
chills 56.6%
pyrexia 52.8%
nausea 45.3%
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
pyrexia 68.4%
chills 50%
nausea 47.4%
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
nausea 50%
pyrexia 50%
dyspnoea 42.9%
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
chills 46.4%
asthenia 42.9%
pyrexia 42.9%
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
3.2/4 mg
anaemia 80%
decreased appetite 80%
fatigue 80%
NCT02009449 · Phase 1 · registry result, not featured evidence
3.2/4 mg
fatigue 100%
anaemia 80%
headache 60%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
1.6/2 mg
anaemia 75.2%
fatigue 59%
thrombocytopenia 59%
NCT02009449 · Phase 1 · registry result, not featured evidence
1.6/2 mg
fatigue 85.3%
anaemia 76.5%
thrombocytopenia 58.8%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
1.6/2 mg
anaemia 68.4%
fatigue 59.6%
cough 42.1%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
constipation 66.7%
decreased appetite 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.8/1 mg
fatigue 88.9%
nausea 83.3%
anaemia 77.8%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
thrombocytopenia 66.7%
fatigue 50%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
fatigue 66.7%
thrombocytopenia 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
fatigue 100%
decreased appetite 66.7%
lipase increased 50%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
fatigue 85.7%
thrombocytopenia 71.4%
anaemia 57.1%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
activated partial thromboplastin time prolonged 100%
alanine aminotransferase increased 100%
anaemia 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 100%
fatigue 100%
thrombocytopenia 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
anaemia 83.3%
fatigue 83.3%
nausea 83.3%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.4/0.5 mg
anaemia 100%
dyspnoea 66.7%
fatigue 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
thrombocytopenia 100%
fatigue 66.7%
anaemia 33.3%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
fatigue 100%
anaemia 80%
hypokalaemia 60%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.2/0.25 mg
anaemia 50%
fatigue 50%
injection site erythema 50%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.2/0.25 mg
asthenia 100%
neutropenia 100%
spermatic cord disorder 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.08/0.1 mg
injection site erythema 75%
abdominal distension 50%
abdominal pain 50%
NCT02009449 · Phase 1 · registry result, not featured evidence
280 mg PO BID
aspartate aminotransferase increased 14.3%
cough 14.3%
fatigue 14.3%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg / 280 mg
anemia 66.7%
back pain 66.7%
diarrhea 66.7%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg PO BID
lipase increased 66.7%
alkaline phosphatase increased 33.3%
anorexia 33.3%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg PO daily
hepatobiliary disorders - other, specify 100%
abdominal pain 66.7%
back pain 66.7%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination

Colorectal Cancer

Shared mechanism: PD-1 · full Colorectal Cancer pipeline

Nivolumab

Marketed by Bristol-Myers Squibb and partners

Approved in Colorectal Cancermonoclonal antibody
Weak signal

NCT02060188 · Phase 2 · completed

The study was non-randomized, unblinded, and had no comparator arm; its 385 participants were distributed across multiple treatment cohorts, including small cohorts. The primary endpoint was investigator-assessed tumor response, and although results were posted, there was no controlled primary comparison to determine whether nivolumab improved outcomes.

Next expected readout: December 2026 · NCT04912765 (registry estimate)

No aligned efficacy figure on record for this race.

Opdivo Qvantig

Marketed by Bristol-Myers Squibb

Approved in Colorectal Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Colorectal Cancer

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Nivolumab: registry results are on file for Colorectal Cancer, but their comparison mappings are not yet available.

Opdivo Qvantig: no structured comparison results are available for Colorectal Cancer.

Head and Neck Squamous Cell Carcinoma

Shared mechanism: PD-1 · full Head and Neck Squamous Cell Carcinoma pipeline

Nivolumab

Marketed by Bristol-Myers Squibb and partners

Approved in Head and Neck Squamous Cell Carcinomamonoclonal antibody
Partial signal

NCT02105636 · Phase 3 · completed

The trial randomly assigned 361 participants to open-label nivolumab or active comparator therapy, so treatment assignment was not blinded. Its objective primary endpoint, overall survival, was statistically significantly better with nivolumab, but the available record does not report a power calculation; these design limitations support a moderate grade rather than the highest grade.

Next expected readout: November 2026 · NCT02955290 (registry estimate)

Reported efficacy

Overall Survival (OS) (From date of randomization to date of death (Up to approximately 18 months)): Overall Survival (OS) (From date of randomization to date of death (Up to approximately 18 months)): Nivolumab 3mg/kg 7.49 Months (95% CI 5.49 to 9.1) | Investigators Choice 5.06 Months (95% CI 4.04 to 6.05) (met)

Result source: NCT02105636

Opdivo Qvantig

Marketed by Bristol-Myers Squibb

Approved in Head and Neck Squamous Cell Carcinomamonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Head and Neck Squamous Cell Carcinoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Opdivo Qvantig: no structured comparison results are available for Head and Neck Squamous Cell Carcinoma.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Nivolumab

ORR 7% (n=14)280 mg PO BID
responder rate · % of participants
No placebo or comparator arm
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
show 16 more results
6.9% (n=29)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
3.2% (n=31)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
13.8% (n=29)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
5.9% (n=68)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
13.3% (n=30)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
6.7% (n=30)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
0% (n=30)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
9.1% (n=11)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
3.4% (n=29)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
0% (n=31)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
10.7% (n=28)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
6% (n=67)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
6.7% (n=30)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
16.7% (n=30)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
0% (n=30)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
9.1% (n=11)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
Overall Survival 12.3 months4 mg/kg + 3 mg/kg Q2W
time to event · months
No placebo or comparator arm
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
show 7 more results
4.7 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
6.4 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
5.6 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
13.9 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
NA months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
8.1 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
5.3 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
Overall Survival Rate at 12 51.1% (n=30) @ 52wk4 mg/kg + 3 mg/kg Q2W
responder rate · % of participants
No placebo or comparator arm
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
show 7 more results
29.2% (n=31) @ 52wk4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
42.5% (n=30) @ 52wk4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
27.2% (n=68) @ 52wk4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
52.9% (n=31) @ 52wk4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
77.8% (n=30) @ 52wk4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
35% (n=30) @ 52wk4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
36.4% (n=11) @ 52wk4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
Duration of Response 8.9 months4 mg/kg + 3 mg/kg Q2W
time to event · months
No placebo or comparator arm
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
show 6 more results
16.2 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
NA months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
12.7 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
7.3 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
NA months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
NA months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
PFS 2.8 months4 mg/kg + 3 mg/kg Q2W
time to event · months
No placebo or comparator arm
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
show 7 more results
1.9 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
1.8 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
1.7 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
2 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
2.9 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
1.8 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
1.8 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
Available safety results

Nivolumab

Dropout rate
0%280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
show 11 more results
0%140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%6 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
0%6 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
—4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
0%4 mg/kg + 3 mg/kg Q3W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
0%4 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
25%2 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
0%2 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
—1 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
—280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
show 11 more results
—140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—6 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
—6 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
—4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
—4 mg/kg + 3 mg/kg Q3W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
—4 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
—2 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
—2 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
—1 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
14.3%280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
show 11 more results
0%140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
66.7%140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
100%140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
50%6 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
54.5%6 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
52.1%4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
50%4 mg/kg + 3 mg/kg Q3W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
10%4 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
33.3%2 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
33.3%2 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
50%1 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
280 mg PO BID
aspartate aminotransferase increased 14.3%
cough 14.3%
fatigue 14.3%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
show 11 more results
140 mg / 280 mg
anemia 66.7%
back pain 66.7%
diarrhea 66.7%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg PO BID
lipase increased 66.7%
alkaline phosphatase increased 33.3%
anorexia 33.3%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg PO daily
hepatobiliary disorders - other, specify 100%
abdominal pain 66.7%
back pain 66.7%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
6 mg/kg + 3 mg/kg Q2W
fatigue 100%
dehydration 83.3%
periorbital oedema 83.3%
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
6 mg/kg Q2W
aspartate aminotransferase increased 60%
blood creatine phosphokinase increased 40%
fatigue 40%
NCT02526017 · Phase 1 · registry result, not featured evidence
4 mg/kg + 3 mg/kg Q2W
fatigue 55.8%
blood creatine phosphokinase increased 47.2%
periorbital oedema 46%
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
4 mg/kg + 3 mg/kg Q3W
candida infection 40%
dizziness 40%
fall 40%
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
4 mg/kg Q2W
abdominal pain 45.5%
aspartate aminotransferase increased 45.5%
fatigue 45.5%
NCT02526017 · Phase 1 · registry result, not featured evidence
2 mg/kg + 3 mg/kg Q2W
amylase increased 33.3%
arthralgia 33.3%
aspartate aminotransferase increased 33.3%
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
2 mg/kg Q2W
fatigue 66.7%
blood alkaline phosphatase increased 33.3%
blood bilirubin increased 33.3%
NCT02526017 · Phase 1 · registry result, not featured evidence
1 mg/kg + 3 mg/kg Q2W
anaemia 50%
amylase increased 25%
aspartate aminotransferase increased 25%
NCT02526017 · Phase 1 · registry result, not featured evidence · combination

Renal Cell Carcinoma

Shared mechanism: PD-1 · full Renal Cell Carcinoma pipeline

Nivolumab

Marketed by Bristol-Myers Squibb and partners

Approved in Renal Cell Carcinomamonoclonal antibody
Partial signal

NCT02231749 · Phase 3 · completed

The trial was randomized and actively controlled, with 550 patients receiving nivolumab plus ipilimumab and 546 receiving sunitinib, but it was open-label. Its objective clinical endpoints were favorable for the nivolumab combination, with statistically significant comparisons reported for response rate, overall survival, and progression-free survival; however, the registry does not document the power calculation needed to establish adequate powering, so this is moderate evidence rather than strong evidence.

Next expected readout: December 2026 · NCT05263050 (registry estimate)

Reported efficacy

Overall Survival (OS) at Primary Endpoint (Randomization until 398 deaths, up to May 2015 (approximately 30 months)): Overall Survival (OS) at Primary Endpoint (Randomization until 398 deaths, up to May 2015 (approximately 30 months)): Nivolumab 25 months | Everolimus 19.55 months (95% CI 17.64 to 23.06) (met)

Result source: NCT01668784

Opdivo Qvantig

Marketed by Bristol-Myers Squibb

Approved in Renal Cell Carcinomamonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Renal Cell Carcinoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Opdivo Qvantig: registry results are on file for Renal Cell Carcinoma, but their comparison mappings are not yet available.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Nivolumab

ORR 56.6% (n=53)30 mg
absolute value · percentage points
No placebo or comparator arm
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
22.7% (n=22)30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
16.7% (n=6)30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
Disease Control 84.9% (n=53)30 mg
absolute value · percentage points
No placebo or comparator arm
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
68.2% (n=22)30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
66.7% (n=6)30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
Duration of Response NA months30 mg
time to event · months
No placebo or comparator arm
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
show 9 more results
7.38 months*30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 32 weeks as posted
20.63 months*30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 89.4 weeks as posted
8.9 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
16.2 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
NA months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
12.7 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
7.3 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
NA months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
NA months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
PFS 18.37 months30 mg
time to event · months
No placebo or comparator arm
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 79.6 weeks as posted
show 10 more results
2.33 months*30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 10.1 weeks as posted
3.37 months*30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 14.6 weeks as posted
2.8 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
1.9 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
1.8 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
1.7 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
2 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
2.9 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
1.8 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
1.8 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
ORR 20% (n=5)3.2/4 mg
event count · % of participants
No placebo or comparator arm
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 1 Participants as posted
show 21 more results
20% (n=5)*3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
6.3% (n=95)*1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 6 Participants as posted
10.7% (n=28)*1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
39.6% (n=48)*1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 19 Participants as posted
0% (n=5)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted
46.7% (n=15)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted
0% (n=6)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
16.7% (n=6)*0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
20% (n=5)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
35.7% (n=14)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted
100% (n=1)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
0% (n=5)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
0% (n=6)*0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted
33.3% (n=3)*0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
20% (n=5)*0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
0% (n=4)*0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
0% (n=5)*0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted
25% (n=4)*0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
0% (n=4)*0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted
14.9% (n=429)*0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 64 Participants as posted
17.6% (n=17)*
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
ORR 7% (n=14)280 mg PO BID
responder rate · % of participants
No placebo or comparator arm
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
show 16 more results
6.9% (n=29)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
3.2% (n=31)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
13.8% (n=29)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
5.9% (n=68)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
13.3% (n=30)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
6.7% (n=30)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
0% (n=30)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
9.1% (n=11)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
3.4% (n=29)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
0% (n=31)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
10.7% (n=28)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
6% (n=67)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
6.7% (n=30)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
16.7% (n=30)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
0% (n=30)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
9.1% (n=11)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
Overall Survival 12.3 months4 mg/kg + 3 mg/kg Q2W
time to event · months
No placebo or comparator arm
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
show 7 more results
4.7 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
6.4 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
5.6 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
13.9 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
NA months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
8.1 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
5.3 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
Overall Survival Rate at 12 51.1% (n=30) @ 52wk4 mg/kg + 3 mg/kg Q2W
responder rate · % of participants
No placebo or comparator arm
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
show 7 more results
29.2% (n=31) @ 52wk4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
42.5% (n=30) @ 52wk4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
27.2% (n=68) @ 52wk4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
52.9% (n=31) @ 52wk4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
77.8% (n=30) @ 52wk4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
35% (n=30) @ 52wk4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
36.4% (n=11) @ 52wk4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
Available safety results

Nivolumab

Dropout rate
100%40 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
show 47 more results
100%30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
97.5%30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
100%20 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
0%0.009 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
20%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
17.2%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
10.5%Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
100%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
99.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
96.5%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
85.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
0%280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%6 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
0%6 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
—4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
0%4 mg/kg + 3 mg/kg Q3W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
0%4 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
25%2 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
0%2 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
—1 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
—40 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
show 47 more results
—30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
—30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
—20 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
—0.009 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—6 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
—6 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
—4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
—4 mg/kg + 3 mg/kg Q3W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
—4 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
—2 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
—2 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
—1 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
57.1%40 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
show 47 more results
85.7%30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
49.4%30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
33.3%20 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
66.7%0.009 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
50%0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
36%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
44.7%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
60%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
62.5%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
42.1%Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
40%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
60%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
51.3%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
47.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
56.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
55.6%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
66.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
66.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
16.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
57.1%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
20%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
40%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
0%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
75%0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
14.3%280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
66.7%140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
100%140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
50%6 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
54.5%6 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
52.1%4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
50%4 mg/kg + 3 mg/kg Q3W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
10%4 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
33.3%2 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
33.3%2 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
50%1 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
40 mg
anaemia 57.1%
decreased appetite 57.1%
contusion 42.9%
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
show 45 more results
30 mg
fatigue 71.4%
weight decreased 71.4%
anaemia 57.1%
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
30 mg
fatigue 65.8%
nausea 55.7%
diarrhoea 53.2%
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
20 mg
diarrhoea 66.7%
dyspnoea 66.7%
fatigue 66.7%
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
0.009 mg/kg q3w + 360 mg q3w
pyrexia 100%
rash 100%
chills 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q3w + 240 mg q2w
arthralgia 100%
fatigue 100%
headache 100%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q2w + 240 mg q2w
chills 100%
pyrexia 100%
back pain 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q3w + 360 mg q3w
fatigue 76%
chills 64%
cough 60%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q3w + 360 mg q3w
fatigue 50.6%
pyrexia 47.9%
nausea 40.1%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.003 mg/kg q2w + 240 mg q2w
chills 100%
nasal congestion 100%
arthralgia 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 90%
diarrhoea 80%
nausea 80%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
diarrhoea 75%
influenza like illness 75%
pruritus 75%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
decreased appetite 100%
fatigue 100%
influenza like illness 100%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 78.9%
influenza like illness 68.4%
nausea 57.9%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
3.2/4 mg
anaemia 80%
decreased appetite 80%
fatigue 80%
NCT02009449 · Phase 1 · registry result, not featured evidence
3.2/4 mg
fatigue 100%
anaemia 80%
headache 60%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
1.6/2 mg
anaemia 75.2%
fatigue 59%
thrombocytopenia 59%
NCT02009449 · Phase 1 · registry result, not featured evidence
1.6/2 mg
fatigue 85.3%
anaemia 76.5%
thrombocytopenia 58.8%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
1.6/2 mg
anaemia 68.4%
fatigue 59.6%
cough 42.1%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
constipation 66.7%
decreased appetite 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.8/1 mg
fatigue 88.9%
nausea 83.3%
anaemia 77.8%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
thrombocytopenia 66.7%
fatigue 50%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
fatigue 66.7%
thrombocytopenia 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
fatigue 100%
decreased appetite 66.7%
lipase increased 50%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
fatigue 85.7%
thrombocytopenia 71.4%
anaemia 57.1%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
activated partial thromboplastin time prolonged 100%
alanine aminotransferase increased 100%
anaemia 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 100%
fatigue 100%
thrombocytopenia 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
anaemia 83.3%
fatigue 83.3%
nausea 83.3%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.4/0.5 mg
anaemia 100%
dyspnoea 66.7%
fatigue 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
thrombocytopenia 100%
fatigue 66.7%
anaemia 33.3%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
fatigue 100%
anaemia 80%
hypokalaemia 60%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.2/0.25 mg
anaemia 50%
fatigue 50%
injection site erythema 50%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.2/0.25 mg
asthenia 100%
neutropenia 100%
spermatic cord disorder 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.08/0.1 mg
injection site erythema 75%
abdominal distension 50%
abdominal pain 50%
NCT02009449 · Phase 1 · registry result, not featured evidence
280 mg PO BID
aspartate aminotransferase increased 14.3%
cough 14.3%
fatigue 14.3%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg / 280 mg
anemia 66.7%
back pain 66.7%
diarrhea 66.7%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg PO BID
lipase increased 66.7%
alkaline phosphatase increased 33.3%
anorexia 33.3%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg PO daily
hepatobiliary disorders - other, specify 100%
abdominal pain 66.7%
back pain 66.7%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
6 mg/kg + 3 mg/kg Q2W
fatigue 100%
dehydration 83.3%
periorbital oedema 83.3%
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
6 mg/kg Q2W
aspartate aminotransferase increased 60%
blood creatine phosphokinase increased 40%
fatigue 40%
NCT02526017 · Phase 1 · registry result, not featured evidence
4 mg/kg + 3 mg/kg Q2W
fatigue 55.8%
blood creatine phosphokinase increased 47.2%
periorbital oedema 46%
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
4 mg/kg + 3 mg/kg Q3W
candida infection 40%
dizziness 40%
fall 40%
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
4 mg/kg Q2W
abdominal pain 45.5%
aspartate aminotransferase increased 45.5%
fatigue 45.5%
NCT02526017 · Phase 1 · registry result, not featured evidence
2 mg/kg + 3 mg/kg Q2W
amylase increased 33.3%
arthralgia 33.3%
aspartate aminotransferase increased 33.3%
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
2 mg/kg Q2W
fatigue 66.7%
blood alkaline phosphatase increased 33.3%
blood bilirubin increased 33.3%
NCT02526017 · Phase 1 · registry result, not featured evidence
1 mg/kg + 3 mg/kg Q2W
anaemia 50%
amylase increased 25%
aspartate aminotransferase increased 25%
NCT02526017 · Phase 1 · registry result, not featured evidence · combination

Metastatic Colorectal Cancer

Shared mechanism: PD-1 · full Metastatic Colorectal Cancer pipeline

Nivolumab

Marketed by Bristol-Myers Squibb and partners

Approved in Metastatic Colorectal Cancermonoclonal antibody
Weak signal

NCT02060188 · Phase 2 · completed

The study was non-randomized, unblinded, and had no comparator arm; its 385 participants were distributed across multiple treatment cohorts, including small cohorts. The primary endpoint was investigator-assessed tumor response, and although results were posted, there was no controlled primary comparison to determine whether nivolumab improved outcomes.

Next expected readout: December 2027 · NCT04017650 (registry estimate)

No aligned efficacy figure on record for this race.

Opdivo Qvantig

Marketed by Bristol-Myers Squibb

Approved in Metastatic Colorectal Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Metastatic Colorectal Cancer

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Nivolumab: registry results are on file for Metastatic Colorectal Cancer, but their comparison mappings are not yet available.

Opdivo Qvantig: no structured comparison results are available for Metastatic Colorectal Cancer.

Advanced Metastatic Colorectal Cancer

Shared mechanism: PD-1 · full Advanced Metastatic Colorectal Cancer pipeline

Nivolumab

Marketed by Bristol-Myers Squibb and partners

Approved in Advanced Metastatic Colorectal Cancermonoclonal antibody
Weak signal

NCT02060188 · Phase 2 · completed

The study was non-randomized, unblinded, and had no comparator arm; its 385 participants were distributed across multiple treatment cohorts, including small cohorts. The primary endpoint was investigator-assessed tumor response, and although results were posted, there was no controlled primary comparison to determine whether nivolumab improved outcomes.

Next expected readout: December 2027 · NCT04017650 (registry estimate)

No aligned efficacy figure on record for this race.

Opdivo Qvantig

Marketed by Bristol-Myers Squibb

Approved in Advanced Metastatic Colorectal Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Advanced Metastatic Colorectal Cancer

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Nivolumab: registry results are on file for Advanced Metastatic Colorectal Cancer, but their comparison mappings are not yet available.

Opdivo Qvantig: no structured comparison results are available for Advanced Metastatic Colorectal Cancer.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Nivolumab's landscape · Opdivo Qvantig's landscape